Results 41 to 50 of about 2,368 (193)
Background Respiratory syncytial virus (RSV) remains a leading cause of medically attended lower respiratory tract disease (MA-LRTD) among infants in Japan.
Naruhiko Ishiwada +6 more
doaj +1 more source
Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study. [PDF]
Introduction: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants. In 2024, the monoclonal antibody nirsevimab became available in Italy for all newborns during their first RSV season. Aims: The
La Regina DP +9 more
europepmc +2 more sources
Summary: Background: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab (a long-acting monoclonal antibody designed to prevent respiratory syncytial virus infections) during the first season of implementation.
Charlotte Ocana de Sentuary +10 more
doaj +1 more source
Abstract Infectious diseases remain a leading cause of morbidity and mortality among pediatric transplant recipients, despite significant advances in transplantation management. Vaccination is the most effective strategy to prevent infections; however, its efficacy is hindered in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT)
Valeria Casotti +35 more
wiley +1 more source
Respiratory Syncytial Virus Vaccination Is Associated With Increased Odds of Preterm Birth
ABSTRACT Aim To analyse whether respiratory syncytial virus (RSV) vaccination during pregnancy increases the odds of preterm birth. Methods A rapid review and meta‐analysis was performed. The main outcome was the risk of preterm (gestational week less than 37) birth.
Ilari Kuitunen, Marjut Haapanen
wiley +1 more source
Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner +2 more
wiley +1 more source
Summary: Background: In August 2023, the Centers for Disease Control and Prevention recommended nirsevimab, a long-acting monoclonal antibody, for all U.S. infants aged
Amanda B. Payne +37 more
doaj +1 more source
ABSTRACT Aim This mini review describes the history of infant respiratory syncytial virus (RSV) immunoprophylaxis and the latest advances in this area. It also reviews the efficacy, safety and impact of the recently introduced prophylactic strategies. Method This narrative review is based on a targeted review of published literature, with emphasis on ...
Santtu Heinonen, Pekka Vartiainen
wiley +1 more source
Potential for Nirsevimab use in Pakistan
Respiratory Tract Infections can be classified as upper and lower tract infections. Upper tract infections are more common such as laryngitis and pharyngitis, but the infections of lower respiratory tract are more fatal such as influenza or bronchitis.
Muhammad Moaz, Basum Hayat
openaire +3 more sources
Frequency, Burden and Pathogens of Acute Respiratory Illness in Very Preterm Infants During Infancy
ABSTRACT Aim To describe the frequency, burden, and pathogen profile of acute respiratory illnesses (ARIs) in very preterm infants during the first year after neonatal intensive care unit (NICU) discharge. Methods Very preterm infants were followed prospectively (August 2015–January 2017) with monthly assessments of symptoms, medication use, and ...
Patricia De Gouveia Belinelo +9 more
wiley +1 more source

